Advancements in Lipoprotein(a) Therapies

This chapter explores recent breakthroughs in medications targeting Lipoprotein(a) levels, highlighting the limitations of traditional statins and the potential of newer therapies like PCSK9 inhibitors and antisense oligonucleotides. It also discusses ongoing clinical trials, risks, and the need for population testing and cascade screening for effective cardiovascular disease prevention.